Skip to main content

Table 1 Comparisons of baseline characteristics of female participants in the growth-hormone (GH)-treated and control groups

From: Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial

 

GH (n = 107)

Control (n = 51)

Age (years)

32.96 ± 4.67

32.86 ± 4.32

Infertility (years)

6.21 ± 3.77

6.35 ± 4.64

Body mass index (kg/m2)

22.09 ± 2.71

21.93 ± 2.66

Anti-Mullerian hormone (ng/ml)

2.61 ± 2.05

2.38 ± 2.03

Follicle-stimulating hormone (mIU/ml)

5.79 ± 2.46

6.09 ± 2.33

Luteinizing hormone (mIU/ml)

2.99 ± 1.36

3.13 ± 1.88

Oestradiol (pg/ml)

33.69 ± 16.20

33.55 ± 20.08

Progesterone (mIU/ml)

0.31 ± 0.16

0.31 ± 0.14

Days of gonadotropins (days)

10.11 ± 1.42

10.45 ± 1.94

Total gonadotropin dose (IU)

2402.14 ± 648.33

2604.41 ± 853.42

Endometrial thickness (mm)

9.62 ± 1.88

9.97 ± 1.92

Stimulation protocols

 Antagonist

27/107 (25.23%)

11/51 (21.57%)

 Long protocol

80/107 (74.77%)

40/51 (78.43%)

  1. All variables are presented as mean ± SD. For comparisons between the groups, the Student’s t test was used